Texas Children's Cancer & Hematology Centers Baylor College of Medicine
Welcome,         Profile    Billing    Logout  
 1 Trial 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
McCarthy, Kathy
NCT03690869 / 2023-000604-19: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Calendar Jan 2025 - Dec 2025: From trial n pediatrics with solid tumors
Terminated
1/2
57
US
cemiplimab (monotherapy), REGN2810, Libtayo, cemiplimab (maintenance), Conventional or hypofractionated, Re-irradiation
Regeneron Pharmaceuticals, Pacific Pediatric Neuro-Oncology Consortium
Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
05/23
05/23
SPRINKLE, NCT05309668 / 2020-005608-20: Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

Hourglass Jul 2024 - Dec 2024 : Results from SPRINKLE trial in children aged 1 to 6 years with NF1 related symptomatic, inoperable plexiform neurofibromas
Active, not recruiting
1/2
36
Europe, Japan, US, RoW
Selumetinib granule formulation, Selumetinib capsule formulation
AstraZeneca, Merck Sharp & Dohme LLC
Neurofibromatosis Type 1
04/24
04/28
NCT04796012: VITAS: Atezolizumab in Combination with Chemotherapy for Pediatric Relapsed/refractory Solid Tumors

Recruiting
1/2
23
US
Atezolizumab, Tecentriq, Vincristine, Vincristine Sulfate Injection, Oncovin, Vincasar PES, Vincrex, Irinotecan, Irinotecan Hydrochloride Injection, Campto, Temozolomide, Temozolomide Capsules, Temodar
University of Texas Southwestern Medical Center
Solid Tumor, Rhabdomyosarcoma
01/25
01/25
NCT03478462: Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

Active, not recruiting
1
30
Canada, US, RoW
CLR 131, I-131-CLR1404
Cellectar Biosciences, Inc.
Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma
09/22
12/24
AUGMENT-102, NCT05326516: A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Hourglass Jan 2023 - Mar 2023 : Data from AUGMENT-102 trial for relapsed/refractory leukemias
Completed
1
30
Canada, US
Revumenib, SNDX-5613, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Syndax Pharmaceuticals
Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
07/24
07/24
NCT05918913: Expanded Access Program for Revumenib

Available
N/A
US
Revumenib, SNDX-5613
Syndax Pharmaceuticals
Relapsed/Refractory Acute Leukemia
 
 

Download Options